30-Jun-2020
Redx Circular
Redx Proxy for Use at General Meeting
30-Mar-2020
Redx Redmile Loan announcement
27-Mar-2020
Redx Pharma AGM Letter to Shareholders 2020
Redx Pharma AGM Notice 2020
Redx Pharma AGM Proxy 2020
06-Jan-2020
Rule 2.11 letter to employees
Rule 2.11 letter to shareholders
Redx – Rule 8 Response – Jan 2020
03-Jan-2020
Shareholder Circular Proposed Capitalisation of Loan
18-Jul-2019
Hardman & Co Research Note – 18 July 2019 – Pan-RAF agreement strengthens balance sheet
10-Jul-2019
Hardman & Co Research Note – 10 July 2019 – Phase I trial resumed
28-Dec-2018
Notice of AGM
30-Nov-2018
Hardman & Co Research Note – 30 Nov 2018 – RXC006: first anti-fibrosis development candidate
27-Nov-2018
Hardman & Co Research Note – 27 Nov 2018 – Streamlined, focused and good value
09-Nov-2018
Hardman & Co Research Note – 9 Nov 2018 – ROCK2 inhibitors in chronic kidney disease
02-Oct-2018
Hardman & Co Research Note – 2 Oct 2018 – Redx Pharma Strategy Launch
06-Sep-2018
Hardman & Co Research Note – 6 Sep 2018 – Back to the clinic
18-Jun-2018
Hardman & Co Research Note – “Focus, Realism and Results”
15-May-2018
Hardman & Co Research Note – Clinical and corporate update
14-Feb-2018
Hardman & Co Research Note – 14 Feb 2018 – RXC004 in the clinic
12-Feb-2018
13-Nov-2017
Hardman & Co Research Note
06-Nov-2017
Shareholder Letter
Corporate Presentation
10-Aug-2017
The Joint Administrators’ Proposals
17-May-2017
Presentation – Interim results for the Six Months Ended 31 March 2017
03-Apr-2017
Hardman & Co research note – Gram-negative antibiotics grant
21-Mar-2017
Presentation – Final results for the year ended 30 September 2016
10-Feb-2017
Application Form for Open Share Offer
Proxy for use at General Meeting on 28 February 2017
Circular to Shareholders
12-Dec-2016
Hardman & Co research note – RXC005 BTK inhibitor – watch this space
08-Aug-2016
Hardman & Co research note – Advancing to clinic, increasing value
24-Feb-2016
AGM Presentation for the year to 30 September 2015
22-Jan-2016
Hardman & Co research note – Pipeline progress — Porcupine Inhibitor
27-Mar-2015
Admission to trading on AIM